Open Payments

KARMANOS CANCER HOSPITAL

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230297
Received
$13,755,007 in 2,821 records, 2019 ($110,045 general, $13,644,962 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment12$110,045
2019Research payment2,809$13,644,962

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC822$3,820,4072019
Alkermes, Inc.165$2,133,8802019
TESARO, Inc.88$1,382,3572019
Genentech, Inc.228$744,4782019
E.R. Squibb & Sons, L.L.C.23$657,0782019
PFIZER INC.135$595,0762019
Janssen Research & Development, LLC173$586,5682019
AstraZeneca Pharmaceuticals LP20$467,0002019
Exelixis Inc.51$444,4092019
Eisai Inc.108$315,5522019
Incyte Corporation234$266,0122019
Celgene Corporation5$231,4222019
SEAGEN INC.97$196,7822019
AstraZeneca UK Limited7$187,4172019
ARRAY BIOPHARMA INC39$154,7262019
Kite Pharma, Inc.39$145,0292019
Radius Health, Inc.32$129,7662019
Pharmacyclics LLC, an AbbVie Company70$126,2592019
Bayer Healthcare Pharmaceuticals Inc.51$125,6302019
Novartis Pharmaceuticals Corporation12$110,6052019
Regeneron Pharmaceuticals, Inc.39$78,9152019
Akcea Therapeutics, Inc.1$75,0002019
Astellas Pharma Global Development6$64,1092019
Eli Lilly and Company9$63,1952019
F. Hoffmann-La Roche AG26$56,8352019
Clovis Oncology, Inc.45$56,3592019
Roche Products Limited28$54,8102019
Hoffmann-La Roche Limited25$44,2452019
Acerta Pharma LLC2$41,9922019
Dynavax Technologies Corporation18$36,7092019
Takeda Pharmaceuticals U.S.A., Inc.17$31,3722019
Plexxikon Inc.18$30,9622019
TAIHO ONCOLOGY, INC.12$30,3872019
BIOVERATIV THERAPEUTICS INC.14$29,7992019
EMD Serono, Inc.20$28,6642019
Halozyme Inc15$28,0232019
Corcept Therapeutics30$27,2052019
Daiichi Sankyo Inc.31$25,0902019
Varian Medical Systems, Inc.1$22,0002019
Alnylam Pharmaceuticals Inc.3$19,1622019
ABBVIE INC.15$16,6152019
Ipsen Biopharmaceuticals, Inc4$14,8862019
Amgen Inc.3$10,2542019
PUMA BIOTECHNOLOGY, INC.10$10,2002019
Gilead Sciences, Inc.6$8,0492019
Novocure Inc.4$5,0002019
Chugai Pharmaceutical Co., Ltd.5$4,4672019
GlaxoSmithKline, LLC.1$3,1502019
Agios Pharmaceuticals, Inc.1$3,0002019
Advanced Accelerator Applications1$2,5002019

By nature of payment

NatureRecordsAmount
Research payment2,809$13,644,962
Grant3$79,000
Space rental or facility fees (teaching hospital only)5$22,500
Charitable Contribution2$5,500
Education2$3,045

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Merck Sharp & Dohme LLC$5,452Research paymentIn-kind items and servicesMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-31AstraZeneca Pharmaceuticals LP$4,530Research paymentIn-kind items and servicesIMFINZI Drug, OncologyA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co2019
2019-12-31Merck Sharp & Dohme LLC$4,481Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2019
2019-12-31AstraZeneca Pharmaceuticals LP$3,561Research paymentIn-kind items and servicesPh2a Montherapy RCC study2019
2019-12-31AstraZeneca Pharmaceuticals LP$1,655Research paymentIn-kind items and servicesPhase I dose escalation and expansion to establish tolerated combination of AZD2014 palbociclib and fulvestrant triplet 2019
2019-12-31Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2019
2019-12-31Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYPhase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-12019
2019-12-31Merck Sharp & Dohme LLC$545Research paymentIn-kind items and servicesMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-31AstraZeneca Pharmaceuticals LP$300Research paymentIn-kind items and servicesStudy of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer2019
2019-12-31AstraZeneca UK Limited$37Research paymentIn-kind items and servicesIMFINZI Drug, OncologyA Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa2019
2019-12-31AstraZeneca UK Limited$34Research paymentIn-kind items and servicesLYNPARZA Drug, OncologyOlaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have 2019
2019-12-31AstraZeneca Pharmaceuticals LP$12Research paymentIn-kind items and servicesLYNPARZA Drug, OncologyThis is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo2019
2019-12-30TESARO, Inc.$26,762Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYPHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F2019
2019-12-30Janssen Research & Development, LLC$2,643Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$1,631Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$1,384Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-30Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$608Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-30Janssen Research & Development, LLC$398Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-30Janssen Research & Development, LLC$68Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2019
2019-12-27Merck Sharp & Dohme LLC$9,808Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2019
2019-12-27Merck Sharp & Dohme LLC$8,178Research paymentIn-kind items and servicesMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-27Novocure Inc.$1,000Research paymentCash or cash equivalentOptune Device, OncologyEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and2019
2019-12-27Merck Sharp & Dohme LLC$990Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2019
2019-12-27Merck Sharp & Dohme LLC$818Research paymentIn-kind items and servicesMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-23Genentech, Inc.$54,047Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22019
2019-12-23Exelixis Inc.$10,925Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-12-23Merck Sharp & Dohme LLC$10,826Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2019
2019-12-23Exelixis Inc.$3,069Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-12-23Exelixis Inc.$1,950Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-12-23Janssen Research & Development, LLC$1,699Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-23Exelixis Inc.$1,144Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-12-23Genentech, Inc.$800Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2019
2019-12-20Genentech, Inc.$4,150Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2019
2019-12-20Genentech, Inc.$3,700Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2019
2019-12-20Genentech, Inc.$3,385Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2019
2019-12-20Merck Sharp & Dohme LLC$97Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother2019
2019-12-19Kite Pharma, Inc.$27,584Research paymentCash or cash equivalentYescarta Drug, ONCPA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non2019
2019-12-19Merck Sharp & Dohme LLC$27,065Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli2019
2019-12-19Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$23,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Alkermes, Inc.$6,057Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19PUMA BIOTECHNOLOGY, INC.$1,000Research paymentCash or cash equivalentNerlynx Drug, OncologyA Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib2019
2019-12-19Bayer Healthcare Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentNon-CoveredBAY94-9343 Solid Tumor Multi Cohort Trial2019
2019-12-19Janssen Research & Development, LLC$920Research paymentCash or cash equivalentPhase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus 2019
2019-12-19Janssen Research & Development, LLC$811Research paymentCash or cash equivalentA Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment2019
2019-12-19Alkermes, Inc.$792Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Merck Sharp & Dohme LLC$400Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2019
2019-12-19Pharmacyclics LLC, an AbbVie Company$336Research paymentCash or cash equivalentIbrutinib Drug, OncologyPCYC-1128-CA2019
2019-12-19Alkermes, Inc.$300Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-19Regeneron Pharmaceuticals, Inc.$106Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-12-19Alkermes, Inc.$62Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-18SEAGEN INC.$16,950Research paymentCash or cash equivalentADCETRIS Biological, OncologyA Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Abov2019
2019-12-18Regeneron Pharmaceuticals, Inc.$7,237Research paymentCash or cash equivalentPhase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl2019
2019-12-18Alkermes, Inc.$3,700Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-12-18Regeneron Pharmaceuticals, Inc.$2,059Research paymentCash or cash equivalentPhase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl2019
2019-12-18Regeneron Pharmaceuticals, Inc.$1,119Research paymentCash or cash equivalentPhase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl2019
2019-12-18Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentPhase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl2019
2019-12-18Merck Sharp & Dohme LLC$798Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous2019
2019-12-18Merck Sharp & Dohme LLC$342Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous2019
2019-12-18Merck Sharp & Dohme LLC$244Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the 2019
2019-12-17Merck Sharp & Dohme LLC$6,500Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli2019
2019-12-17BIOVERATIV THERAPEUTICS INC.$4,343Research paymentCash or cash equivalentBIVV003 DrugA Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantati2019
2019-12-17Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli2019
2019-12-17Corcept Therapeutics$98Research paymentCash or cash equivalentCORT125281-6012019
2019-12-16Bayer Healthcare Pharmaceuticals Inc.$3,856Research paymentCash or cash equivalentNon-CoveredBAY1163877 I/O combination in Urothelial Bladder Cancer2019
2019-12-16Bayer Healthcare Pharmaceuticals Inc.$2,132Research paymentCash or cash equivalentNon-CoveredBAY1163877 I/O combination in Urothelial Bladder Cancer2019
2019-12-16Bayer Healthcare Pharmaceuticals Inc.$1,623Research paymentCash or cash equivalentNon-CoveredBAY1163877 I/O combination in Urothelial Bladder Cancer2019
2019-12-16Eisai Inc.$1,451Research paymentCash or cash equivalentLenvima Drug, OncologyA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit2019
2019-12-16PUMA BIOTECHNOLOGY, INC.$1,200Research paymentCash or cash equivalentNerlynx Drug, OncologyA Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib2019
2019-12-16Janssen Research & Development, LLC$1,155Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 2019
2019-12-16Bayer Healthcare Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentNon-CoveredBAY1163877 I/O combination in Urothelial Bladder Cancer2019
2019-12-16Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2019
2019-12-16Merck Sharp & Dohme LLC$975Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2019
2019-12-16Merck Sharp & Dohme LLC$646Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the 2019
2019-12-16Bayer Healthcare Pharmaceuticals Inc.$608Research paymentCash or cash equivalentNon-CoveredBAY1163877 I/O combination in Urothelial Bladder Cancer2019
2019-12-13Janssen Research & Development, LLC$1,998Research paymentCash or cash equivalentBiomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer2019
2019-12-13EMD Serono, Inc.$1,713Research paymentCash or cash equivalentBavencio Biological, OncologyEMR 100070-0012019
2019-12-13Regeneron Pharmaceuticals, Inc.$1,020Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, 2019
2019-12-13Plexxikon Inc.$330Research paymentCash or cash equivalentA Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors2019
2019-12-13Plexxikon Inc.$325Research paymentCash or cash equivalentPLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors2019
2019-12-12Alkermes, Inc.$75,511Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-12F. Hoffmann-La Roche AG$8,186Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyATEZOLIZUMAB RADIUM IN CASTRATE RESISTANT PROSTATE CANCER2019
2019-12-12PFIZER INC.$1,998Research paymentCash or cash equivalentPHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN2019
2019-12-12Janssen Research & Development, LLC$1,814Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject2019
2019-12-12Merck Sharp & Dohme LLC$1,505Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2019
2019-12-12Merck Sharp & Dohme LLC$1,500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph2019
2019-12-12Focal Therapeutics, Inc.$750Research paymentCash or cash equivalentDXA System Device, Breast and Skeletal Health17-022019
2019-12-12Merck Sharp & Dohme LLC$231Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2019
2019-12-12Incyte Corporation$125Research paymentCash or cash equivalentA Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With 2019
2019-12-11Alkermes, Inc.$82,143Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-12-11Celgene Corporation$66,987Research paymentCash or cash equivalentJCAR017 DrugA Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-e2019
2019-12-11TESARO, Inc.$26,762Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYPHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE2019
2019-12-11Advanced Accelerator Applications$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentLutathera Drug, Radioactive targeted therapy - Neuroendocrine tumors2019
2019-12-11Merck Sharp & Dohme LLC$918Research paymentCash or cash equivalentMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-11Merck Sharp & Dohme LLC$305Research paymentCash or cash equivalentMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-11Merck Sharp & Dohme LLC$150Research paymentCash or cash equivalentMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-10Genentech, Inc.$158Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2019
2019-12-09Clovis Oncology, Inc.$2,191Research paymentCash or cash equivalentRubraca Drug, ONCOLOGYA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro2019
2019-12-09SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-12-09SEAGEN INC.$1,000Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-12-09SEAGEN INC.$650Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-12-06Janssen Research & Development, LLC$54,660Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Merck Sharp & Dohme LLC$21,652Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the 2019
2019-12-06Janssen Research & Development, LLC$2,091Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Janssen Research & Development, LLC$2,035Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Janssen Research & Development, LLC$2,007Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Janssen Research & Development, LLC$2,000Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Janssen Research & Development, LLC$1,384Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Genentech, Inc.$845Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2019
2019-12-06Janssen Research & Development, LLC$340Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2019
2019-12-06Alkermes, Inc.$175Research paymentIn-kind items and servicesA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-06Alkermes, Inc.$123Research paymentIn-kind items and servicesA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2019
2019-12-06Janssen Research & Development, LLC$105Research paymentCash or cash equivalentPhase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus 2019
2019-12-05PFIZER INC.$16,783Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS2019
2019-12-05Genentech, Inc.$7,561Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2019
2019-12-05Genentech, Inc.$5,977Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPH II PLACEBO CONTROLLED OF MTIG7192A AND ATEZO IN NSCLC2019
2019-12-05TESARO, Inc.$2,554Research paymentCash or cash equivalentZEJULA Drug, ONCOLOGYPHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE2019
2019-12-05ARRAY BIOPHARMA INC$1,615Research paymentCash or cash equivalentA Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors2019
2019-12-05Halozyme Inc$1,500Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase 2019
2019-12-05Exelixis Inc.$1,000Research paymentCash or cash equivalentCabozantinib Drug, OncologyA Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus2019
2019-12-04Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli2019
2019-12-04Ipsen Biopharmaceuticals, Inc$4,879Research paymentCash or cash equivalentSOMATULINE DEPOT Drug, Oncology/EndocrinologyA Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide AutogelDep2019
2019-12-04SEAGEN INC.$1,500Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-12-04SEAGEN INC.$1,320Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-12-04SEAGEN INC.$1,000Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2019
2019-12-04SEAGEN INC.$1,000Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-12-04Merck Sharp & Dohme LLC$75Research paymentCash or cash equivalentMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019
2019-12-03TESARO, Inc.$26,762Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYPHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F2019
2019-12-03PFIZER INC.$20,094Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002019
2019-12-03Genentech, Inc.$7,333Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2019
2019-12-03Merck Sharp & Dohme LLC$4,946Research paymentCash or cash equivalentMK-6482 Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Renal Cell Carcinoma2019
2019-12-03Celgene Corporation$3,711Research paymentCash or cash equivalentReblozyl Drug, Beta ThalassemiaA Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (2019
2019-12-03PFIZER INC.$3,428Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002019
2019-12-03PFIZER INC.$2,350Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002019
2019-12-03Genentech, Inc.$1,754Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2019
2019-12-03PFIZER INC.$1,500Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB2019
2019-12-03F. Hoffmann-La Roche AG$1,000Research paymentCash or cash equivalentTarceva Drug, BioOncology1L NSCLC DX ALL COMER SQUAMOUS2019
2019-12-03BIOVERATIV THERAPEUTICS INC.$1,000Research paymentCash or cash equivalentBIVV003 DrugA Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantati2019
2019-12-03Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2019
2019-12-03PFIZER INC.$732Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002019
2019-12-03Eisai Inc.$400Research paymentCash or cash equivalentLenvima Drug, OncologyA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit2019
2019-12-03PFIZER INC.$250Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB2019
2019-12-03Genentech, Inc.$80Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2019
2019-12-02Regeneron Pharmaceuticals, Inc.$4,212Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-12-02Genentech, Inc.$608Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyLCMC32019
2019-12-02Genentech, Inc.$352Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyLCMC32019
2019-12-02Janssen Research & Development, LLC$316Research paymentCash or cash equivalentPhase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus 2019
2019-11-29Janssen Research & Development, LLC$5,594Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject2019
2019-11-29Janssen Research & Development, LLC$3,474Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-11-28Pharmacyclics LLC, an AbbVie Company$1,500Research paymentCash or cash equivalentIbrutinib Drug, OncologyPCYC-1140-IM2019
2019-11-28Pharmacyclics LLC, an AbbVie Company$1,000Research paymentCash or cash equivalentIbrutinib Drug, OncologyPCYC-1140-IM2019
2019-11-28Pharmacyclics LLC, an AbbVie Company$660Research paymentCash or cash equivalentIbrutinib Drug, OncologyPCYC-1140-IM2019
2019-11-27Exelixis Inc.$33,672Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-27Radius Health, Inc.$15,950Research paymentCash or cash equivalentA RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE2019
2019-11-27PFIZER INC.$2,275Research paymentCash or cash equivalentINLYTA Drug, ONCOLOGYA PHASE 1B OPEN LABEL DOSE FINDING STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB AG013736 I2019
2019-11-27PFIZER INC.$1,500Research paymentCash or cash equivalentINLYTA Drug, ONCOLOGYA PHASE 1B OPEN LABEL DOSE FINDING STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB AG013736 I2019
2019-11-27ABBVIE INC.$1,384Research paymentCash or cash equivalentVenclexta Drug, VirologyM13-4942019
2019-11-26Merck Sharp & Dohme LLC$9,359Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2019
2019-11-26Kite Pharma, Inc.$8,776Research paymentCash or cash equivalentYescarta Drug, ONCPA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non2019
2019-11-26Kite Pharma, Inc.$6,279Research paymentCash or cash equivalentYescarta Drug, ONCPA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non2019
2019-11-26Exelixis Inc.$3,884Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Exelixis Inc.$3,884Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Merck Sharp & Dohme LLC$1,500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2019
2019-11-26Plexxikon Inc.$1,500Research paymentCash or cash equivalentA Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors2019
2019-11-26Plexxikon Inc.$1,500Research paymentCash or cash equivalentPLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors2019
2019-11-26Kite Pharma, Inc.$1,000Research paymentCash or cash equivalentA Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma2019
2019-11-26Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2019
2019-11-26Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2019
2019-11-26Exelixis Inc.$760Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Merck Sharp & Dohme LLC$660Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2019
2019-11-26Exelixis Inc.$650Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Exelixis Inc.$650Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Exelixis Inc.$213Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2019
2019-11-26Merck Sharp & Dohme LLC$123Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYPhase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-12019
2019-11-25Janssen Research & Development, LLC$34,870Research paymentCash or cash equivalentA Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject2019
2019-11-25Alkermes, Inc.$4,600Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Alkermes, Inc.$4,300Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Alkermes, Inc.$4,000Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Alkermes, Inc.$4,000Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Alkermes, Inc.$3,700Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Genentech, Inc.$1,500Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPOLARIX2019
2019-11-25Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPOLARIX2019
2019-11-25Kite Pharma, Inc.$163Research paymentCash or cash equivalentYescarta Drug, ONCPA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non2019
2019-11-25Alkermes, Inc.$56Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-25Alkermes, Inc.$56Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2019
2019-11-24Merck Sharp & Dohme LLC$191Research paymentIn-kind items and servicesMK-4280 Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects2019

The latest 200 records of 2,821.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.